Menopause and osteoporosis: The role of HRT

Journal of the American Pharmaceutical Association

Volumn 36, Issue 4, 1996, Pages 234-242

  Carson, D S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DESOGESTREL; ESTRADIOL; ESTROGEN; GESTAGEN; HYPNOTIC AGENT; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; PIPERAZINE ESTRONE SULFATE; PROGESTERONE; UNCLASSIFIED DRUG;

FEMALE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PATIENT EDUCATION; PHARMACIST; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TRANSDERMAL DRUG ADMINISTRATION; VAGINA BLEEDING; WEIGHT GAIN; ARTICLE; DRUG INTERACTION; ECONOMICS; ESTROGEN THERAPY; METABOLISM; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PSYCHOLOGICAL ASPECT;

DRUG INTERACTIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTINS;

EID: 0029918041     PISSN: 10865802     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1086-5802(16)30046-8     Document Type: Review

References (54)

1. E. Barrett-Connor Epidemiology and the menopause: a global overview Int J Fertil. 38 suppl 1 1993 6 14
2. A.O. Moore P.M. Mullins M.C. Pugh Hormonal replacement therapy J.T. DiPiro R.L. Talbert P.E. Hayes Pharmacotherapy: A Pathophysiologic Approach 2nd ed. 1992 Elsevier New York 1241 1250
3. K.T. Khaw The menopause and hormone replacement therapy Postgrad Med J. 68 1992 615 623
4. D.P. Kiel A.J. Baron J.J. Anderson Smoking eliminates the protective effects of oral estrogens on the risk for hip fracture among women Ann Intern Med. 116 1992 716 721
5. A review of osteoporosis Phase III Drug Profiles. 3 1994 1 2
6. Consensus Development Conference: prophylaxis and treatment of osteoporosis Am J Med. 90 1991 107 110
7. L.J. Melton III. How many women have osteoporosis now? J Bone Miner Res. 10 1995 175 177
8. R. Sagraves M.B. O'Connell D.S. Carson APhA Special Report on Therapeutic Options for Osteoporosis 1993 APhA Washington
9. More than hot flushes Lancet. 338 1991 917 918
10. V. Ravnikar Compliance with hormone therapy Am J Obstet Gynecol. 156 1987 1332 1334
11. L.E. Nachtigall Enhancing patient compliance with hormone replacement therapy Obstet Gynecol 75 1990 77S 80S
12. M.E. Quigley P.L. Martin A.M. Burnier Estrogen therapy arrests bone loss in elderly women Am J Obstet Gynecol. 156 1987 1516 1523
13. E.F. Eriksen D.S. Colvard N.J. Berg Evidence of estrogen receptors in normal human osteoblast-like cells Science. 241 1988 84 86
14. B.L. Riggs L.J. Melton The prevention and treatment of osteoporosis N Engl J Med. 327 1992 620 627
15. C. Christiansen M.S. Christensen I. Transbol Bone mass after withdrawal of oestrogen replacement Lancet. 1 1981 459 461
16. M.T.R. Subbiah B. Kessel M. Agrawal Antioxidant potential of specific estrogens on lipid peroxidation J Clin Endocrin Metab. 77 1993 109 157
17. B.R. Bhavnani C.A. Woolever Interaction of ring B unsaturated estrogen with estrogen receptors of human endometrium and rat uterus Steroids. 56 1991 201 210
18. S.A. Washburn M.R. Adams T.B. Clarkson A conjugated equine estrogen with differential effects on uterine weight and plasma cholesterol in the rat Am J Obstet Gynecol. 169 1993 251 326
19. S.M. Troy D.R. Hicks V.D. Parker Differences in pharmacokinetics and comparative bioavailability between Premarin and Estratab in healthy postmenopausal women Curr Ther Res. 55 1994 359 372
20. Prescription drug products B.R. Olin Approved Bioequivalency Codes; Facts and Comparisons. Section I 1995 Facts and Comparisons St. Louis 120 122
21. R.A. Lobo H.N. Nguyen P. Eggena Biologic effects of equilin sulfate in postmenopausal women Fertil Steril. 49 1988 234 238
22. G.V. Upton A. Corbin Contraception for the transitional years of women older than 40 years of age Clin Obstet Gynecol. 35 1992 855 863
23. P.L. Selby M. Peacock The effect of transdermal oestrogen on bone, calcium-regulating hormones and liver in postmenopausal women Clin Endocrinol. 25 1986 543 547
24. F.P. Mandel F.L. Geola O.K. Meldrum Biologic effects of various doses of vaginally administered conjugated equine estrogen in postmenopausal women J Clin Endocrinol Metab. 57 1983 133 139
25. M. Devor E. Barrett-Connor M. Renvall Estrogen replacement therapy and the risk of venous thrombosis Am J Med. 92 1992 275 282
26. E. Barrett-Connor W.V. Brown J. Turner Heart disease risk factors and hormone use in postmenopausal women JAMA. 241 1979 2167 2169
27. R. Lobo Estrogen and the risk of coagulopathy Am J Med. 92 1992 283 284
28. Writing group for the PEPI trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial JAMA. 273 1995 199 208
29. J.C. Stevenson D. Crook I.F. Godsland Oral versus transdermal hormone replacement therapy Int J Fertil. 38 suppl 1 1993 30 35
30. B.W. Walsh I. Schiff B. Rosner Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins N Engl J Med. 325 1991 1196 1204
31. Lipid modifying drugs J.M. McKenney D.W. Hawkins Handbook on the Management of Lipid Disorders 1995 Scientific Therapeutics, Inc Springfield, NJ
32. D.R. Gambrell Jr. Update on hormone replacement therapy Am Fam Physician. 46 suppl 5 1992 87S 96S
33. C. Christiansen Prevention and treatment of osteoporosis with hormone replacement therapy Int J Fertil. 38 suppl 1 1993 45 54
34. R.M. Dickey Managing Contraceptive Pill Patients 7th ed. 1993 Essential Medical Information Systems, Inc Durant, Okla
35. L. Udoff P. Langenberg E.Y. Adashi Combined continuous hormone replacement therapy: a critical review Obstet Gynecol. 86 1995 306 316
36. B. Ettinger J. Selby J.T. Citron Cyclic hormone replacement therapy using quarterly progestin Obstet Gynecol. 83 1994 693 700
37. E.G. Lufkin S.J. Ory Relative value of transdermal and oral estrogen therapy in various clinical situations Mayo Clin Proc. 69 1994 131 135
38. G.A. Colditz S.E. Hankinson D.J. Hunter The use of estrogens and progestins and the risk of breast cancer in postmenopausal women N Engl J Med. 332 1995 1589 1593
39. J.L. Stanford N.S. Weiss L.F. Voigt Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women JAMA. 274 1995 137 142
40. L. Speroff Post-menopausal hormone therapy and breast cancer Obstet Gynecol. 87 1996 44S 54S
41. Fosamax package insert October 1995 Merck Human Health Division West Point, Pa
42. C.Y.C. Pak K. Sakhaee B. Adams-Huet Treatment of postmenopausal osteoporosis with slow-released sodium fluoride: final report of a randomized controlled trial Ann Intern Med. 123 1995 401 408
43. H. Rico M. Revilla E.R. Hernandes Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study Calcif Tissue Int. 56 1995 181 185
44. K. Overgaard Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose response study Calcif Tissue Int. 55 1994 82 86
45. G.P. Lyritis S. Tsakalabos B. Magiasis Analgesic effect of salmon calcitonin on osteoporotic vertebral fractures. Double blind, placebo controlled study Calcif Tissue Int. 49 1991 369 372
46. D. Kritz-Silverman E. Barrett-Connor Long term postmenopausal hormone use, obesity, and fat distribution in older women JAMA. 275 1996 46 49
47. Drug interaction facts D.S. Tatro B.R. Olin 1994 Facts and Comparisons Facts and Comparisons. St. Louis 318 322
48. A. Tosteson D. Rosenthal J. Melton Cost effectiveness of screening peri menopausal white women for osteoporosis: bone densitometry and hormone replacement therapy Ann Intern Med. 113 1990 594 603
49. M. Weinstein Estrogen use in postmenopausal women—costs, risks, and benefits N Engl J Med. 303 1980 308 316
50. A. Tosteson M. Weinstein Cost-effectiveness of hormone replacement therapy after the menopause Baillieres Clin Obstet Gynaecol. 5 1991 943 959
51. M. Weinstein I. Schiff Cost-effectiveness of hormone replacement therapy in the menopause Obstet Gynecol Surv. 38 1983 445 455
52. M. Weinstein A. Tosteson Cost-effectiveness of hormone replacement Ann NY Acad Sci. 592 1990 162 172
53. A. Cheung B. Wren A cost-effectiveness analysis of hormone replacement therapy in the menopause Med J Aust. 156 1992 312 316
54. NIH Consensus Conference Optimal calcium intake: National Institutes of Health Consensus Development Conference Statement on optimal calcium intake JAMA. 272 1994 1942 1948